Fungi have emrged as important pathogens in imrunoccmprcmised children. At the Natimal Cancer Institute, approximately 40% of chi ldren undergoing cancer treatment who succub during periods of prolonged granulocytopenia will have evidence of invasive fun941 disease at postmrtem examinatim. While m s t of these patients have refractory malignancies, in s a w cases fungal infectim has cmtributed to the death of patients undergoing primary cancer treatment. The predominant fungal pathogens which occur in i m o i carprcmised children include Candida and Aspergillus. Less c a m m i i y, infect i m s wi th the Phyccmycetes, Cryptococcus, Trichosporcn or Fusarlun result in serious infectim.
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Both the host and the e n v i r m n t ccntribute to the risk and incidence of infectim. For exawle, certain fungal infectims arise frcm the patient's endogenous flora (e.g., Candida sp) as a cmsequence of cytotoxic and imnmosuppresslve therapies almg with antibiotic selectim. Other fungal organisms (e.g., Aspergil lus) are acquired fran exogenms sources (e.g., spores generattld franospital cmstructim). Geographic variatim in the fungal pathogens (e.g., Cryporccoccus, Hi stop1 asma, Coccidi oides) also alter the patterns of infectim. Similarly, the degree of host ccmprcmise may predispose the patient to certain types of fungal infectim. For exarple, the child with T-cell deficiencies (severe ccnbined i m e deficiency, DiGeorge Syndrm) are at risk for candidal infectim, as are children with adrenal insufficiency anq the syndrcm of chrmic nucocutanecus candidiasls.
Cne of the mjor difficulties with an invasive fungal infecti is the difficulty in diagnosing it accurately. It is often probl atic to determine h w colmizatim with a particular fungal patho' gen per equates with infectim. Moreover, sites of active infection m y be difficult to define, either because of their inaccessability (e.g., pulmary processes) or because of the poor in vitro growth characteristics of the organism. In spite of ccnsiderl--able research effort, virtually ai l of the antigen-detectim assays are limited by a high rate of false negative results. This necessitates that the clinician be aware of the syndrms m s t likely to be caused by invasive fungal infectims and to be prepared to intervene prmtly (and frequently empirically) in their treatm n t .
Unfortunately, the therapeutic agents available to treat and prevent invaslve fungal Infect ims remain suboptimal. Prrphotericin B is still the gold staldard ot therapy but suffers frcm an exten4 slve array of side-effects and frcm a limited efficacy in patients with persistent neutropenia (especially when the offending organism is Aspergi l lus). Recently, encwraginn results have been obtained when mhotericin B has been encapsulated into liposcms and clinical trials using unilmellar and rmltilmllar liposaneencapsulated mphotericin B are in progress. The imidazole antifungal agents (ketoccnazole, clotrimazole, miccnazole) have had demnstable efficacy in imrunocarpranised children with superficidl infectim (e.g., oral rmcositis, chrmic nucocutaneous candidiasi?, esophagitis) but have had limited efficacy for patients with invasive infect im. In a randanized trial that we recently performed at the NCI cmaring oral ketoconazole to intravencus mhotericin B for patients with persistent fever and neutropenia, we observed that whenever an invaslve fungal infecticn emerged in a patient receiving ketocmazole, it invariably progressed, and that the miy iwrovements which cccured took place when the patient was crossed over to amphotericin B. Alternatively, it is clear that anphotericin B is far frcm a panacea since, as noted, it also has a high failure rate in treating Aspergillus or infectims, particularly in patients who remain persistently neutropenic. Althmgh there is little cloclusive supporting data (except for Cryptococcal mnlngitis), sane centers have suggested that an Improved o u t c m can be attained by ccrrbinlng mphotericin B with flucytosine.
b e of the most inportant guiding principles is to institute antifungal therapy as early as possible in the patient's treatmeng cour-se if the clinical setting is ccnpatible with invasive fungal disease. Situaticns in which we have observed a benefit for this strategy include patients with s m t m t i c esophagitis, patients with new pulmary infiltrates which have appeared during antibiot lc treatment and pro1 cnged neut ropeni a, neutropenlc patients with "bulls-eye" leslms a, abdcminal ultrascund or CT scan which are ccmpatible with hepatic candidiasis, patients with persistent granulocytopenia (2 1 week) and fever. P r w t interventim with antitungal therapy can be successful in each of these settings although extended treatmnt ccurses are s m t l m s necessary.
Lhtifungal agents have also been used topically and orally to try to prevent colmlzat l m or invaslm by potential pathogens. While sane success in controlling infecticn with Candida sp has been observed, no beneficial effect m Aspergi 1 lus has been attained.
In enters where a prohibitive incidence of Aspergillus infectim exists, specialized air filtratim systems (e.g., HEPA filters or laminar alr flow rwns) can be used to limit the nuber of Aspergillus spores In the air and to reduce colmiiatim and subsequent infect im.
In s m r y , fungal infectims are a major diagnostic and therar peutic problem for the pediatrician involved in the care of inr nunosuppressed children. Improved diagnostic techniques and more effective therapeutic agents are of critical inportance if the l imitatlms that fmgi place m current treatment strategies are to be overcm.
Do the Vaccines Cause Adverse Reactions?
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A critical question on any vaccination is the harm potentially induced to the vaccinee. A number of var;ous signs and symptoms have been attributed to immunizations, but usually the sugoested causal relationship has been sequential only.
However, p o s t h o e e s t non p r o p t o r h o e .
A vaccination project for elimination of measles, mumps and rubella (MMR) from Finland was started in November 1982. Potential adverse reactions were studied in twins by using the placebo controlled double blind and cross-over fashion. Parents of the twins born during one year were asked for participation. If an agreement was reached, A-twin received the vaccine coded as A, and B-twin received B Another injection was admlnlstered after three w&ks; twin A received vaccine A and twin B vaccine B . At this time both children hid received the live &R vaccine once and placebo once. A questionnaire presenting 16 specific queries was given to the parents at each time In addition, the vaccinators (public health nurses) filled their own forms. At the stage when data of 870 children (435 twin pairs) at the age of 14 months to 6 years had been analyzed, and only the question was answered whether or not a particular sign or symptom was observed within 21 days after vaccination, no statistical significance was reached in any reaction whatsoever between the vaccinees and the placebo controls. Respiratory symptoms, for example, were reported in 17% and 17% after the first injection no matter whether the MMR vaccine or placebo was used. Practically with the same frequency were reported also erythema at the injection site, generalized eczema, irritablity, exhaustion, fever, gastroenteritis, and conjunctivitis.
The conclusion is that although statistical differences between the two qroups might be observed when the reactions are analyzed day-by-day, the vast majority of the so called vaccination reactions were not caused by M R . It is probable that this finding holds true in many other immunizations, too.
